MX9303332A - Analogos de peptidos conformacionalmente restringidos, como agentes antiplaquetarios. - Google Patents

Analogos de peptidos conformacionalmente restringidos, como agentes antiplaquetarios.

Info

Publication number
MX9303332A
MX9303332A MX9303332A MX9303332A MX9303332A MX 9303332 A MX9303332 A MX 9303332A MX 9303332 A MX9303332 A MX 9303332A MX 9303332 A MX9303332 A MX 9303332A MX 9303332 A MX9303332 A MX 9303332A
Authority
MX
Mexico
Prior art keywords
peptides
platelet agents
conformationally restricted
platelet aggregation
restricted analogs
Prior art date
Application number
MX9303332A
Other languages
English (en)
Inventor
Scott L Harbeson
Alan J Bitonti
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Publication of MX9303332A publication Critical patent/MX9303332A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con análogos de péptidos conformacionalmente restringidos como inhibidores de la agregación plaquetaria. Estos compuestos inhiben el enlace del fibrinógeno al receptor integrina GPIIb-IIIa de las plaquetas, el cual inhibe la agregación plaquetaria y por lo tanto estos compuestos actúan como antitrombóticos potentes.
MX9303332A 1992-06-04 1993-06-03 Analogos de peptidos conformacionalmente restringidos, como agentes antiplaquetarios. MX9303332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89421492A 1992-06-04 1992-06-04
US5611193A 1993-05-07 1993-05-07

Publications (1)

Publication Number Publication Date
MX9303332A true MX9303332A (es) 1994-06-30

Family

ID=26734982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9303332A MX9303332A (es) 1992-06-04 1993-06-03 Analogos de peptidos conformacionalmente restringidos, como agentes antiplaquetarios.

Country Status (16)

Country Link
US (1) US6107275A (es)
EP (1) EP0648224B1 (es)
JP (1) JP3398747B2 (es)
KR (1) KR100297184B1 (es)
AT (1) ATE168380T1 (es)
AU (1) AU672010B2 (es)
CA (1) CA2137072C (es)
DE (1) DE69319733T2 (es)
DK (1) DK0648224T3 (es)
ES (1) ES2121088T3 (es)
GR (1) GR3027738T3 (es)
IL (1) IL105885A (es)
MX (1) MX9303332A (es)
NZ (1) NZ253452A (es)
TW (1) TW274085B (es)
WO (1) WO1993024520A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US6117974A (en) * 1991-10-02 2000-09-12 Peptor Limited Libraries of backbone-cyclized peptidomimetics
PT729362E (pt) * 1993-11-19 2000-06-30 Searle & Co Composicao transdermica de n-¬n-¬5-¬4-(aminoiminometil)fenil|-1oxopentil|-l-alfa-aspartil|-l-fenillalanina ou esteres e seus sais farmaceuticamente aceitaveis
US6387880B1 (en) 1994-10-24 2002-05-14 G.D. Searle & Co. Transdermal N-[N-[5-[4-(aminoiminomethly)phenyl]-1-oxopentyl]-L-α-aspartyl]-L-phenylalainine or its esters and their pharmaceutically acceptable salts
DE19653036A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Cyclopeptidderivate
DE19728524A1 (de) 1997-07-04 1999-01-07 Merck Patent Gmbh Cyclische Azapeptide
CA2284459C (en) 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
CA2793838C (en) 2010-03-19 2019-09-17 H. Lee Moffitt Cancer Center & Research Institute, Inc. Integrin interaction inhibitors for the treatment of cancer
US10011635B2 (en) 2013-09-27 2018-07-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1585061A (en) * 1977-03-15 1981-02-25 Nat Res Dev Synthesis of peptides
US5041380A (en) * 1982-08-04 1991-08-20 La Jolla Cancer Research Foundation Tetrapeptide
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
FI84025C (fi) * 1989-06-30 1991-10-10 Jukka Elias Saarikettu Filter som taol hoega temperaturer och foerfarande foer framstaellning daerav.
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
CA2021950A1 (en) * 1989-07-28 1991-01-29 Ruth F. Nutt Fibrinogen receptor antagonists
CA2021951A1 (en) * 1989-07-28 1991-01-29 Ruth F. Nutt Fibrinogen receptor antagonists
US5023233A (en) * 1989-07-28 1991-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds

Also Published As

Publication number Publication date
AU4378393A (en) 1993-12-30
DE69319733T2 (de) 1999-01-14
CA2137072C (en) 2000-06-13
CA2137072A1 (en) 1993-12-09
JPH07507310A (ja) 1995-08-10
KR100297184B1 (ko) 2001-10-22
KR950701935A (ko) 1995-05-17
IL105885A (en) 1999-06-20
US6107275A (en) 2000-08-22
JP3398747B2 (ja) 2003-04-21
GR3027738T3 (en) 1998-11-30
ATE168380T1 (de) 1998-08-15
TW274085B (es) 1996-04-11
EP0648224B1 (en) 1998-07-15
DK0648224T3 (da) 1998-10-26
EP0648224A1 (en) 1995-04-19
DE69319733D1 (de) 1998-08-20
IL105885A0 (en) 1993-10-20
ES2121088T3 (es) 1998-11-16
WO1993024520A1 (en) 1993-12-09
AU672010B2 (en) 1996-09-19
NZ253452A (en) 1996-06-25

Similar Documents

Publication Publication Date Title
ES535842A0 (es) Un procedimiento para preparar octapeptidos lineales
TW363064B (en) Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
ES2155518T3 (es) Compuestos antimicrobianos de amplio espectro y metodo de uso.
BR9713366A (pt) Análogos de heptapeptìdeo oxitocina
MX9303332A (es) Analogos de peptidos conformacionalmente restringidos, como agentes antiplaquetarios.
GR3029931T3 (en) CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa.
DE69723728D1 (de) Totalsynthese des amino hip analogen von didemnin a
ES2132882T3 (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
PT1107981E (pt) Sintese de analogos peptidicos ciclicos de anel modificado
ATE206137T1 (de) Neuartige peptidinhibitoren für opioidrezeptoren
UA41300C2 (uk) Аналоги гормонів-антагоністів lhrh і спосіб їх отримання
NO992298L (no) Konformasjonsbegrensede LH-RH analoger, anvendelse derav og farmas°ytiske sammensetninger inneholdende disse
EA200000197A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
DE69715910T2 (de) Pharmazeutische zusammensetzung enthaltend peptide für die inhibierung der immunoglobulin-rezeptor interaktion
JPS6416792A (en) Guanidine related compound containing tetraphenylborate ion, its production and use thereof in peptide synthesis
JO1362B1 (en) Antagonists that do not contain proline unit and have the effectiveness of vasopressin compounds
WO1998056824A3 (de) Inkorporation von pharmakologisch wirksamen aminosäureanaloga in proteine
NO962204L (no) Dobbeltkjedede hemoregulatoriske peptider